Latest News

For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...

The Sage Group plc ( LON:SGE ) will increase its dividend from last year's comparable payment on the 10th of February...

The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...

Key Insights Insiders appear to have a vested interest in KOSESLtd's growth, as seen by their sizeable ownership 52% of...

The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices closing lower due to weak trade data from China, highlighting global economic uncertainties. Despite these broader market pressures, investors often find potential in smaller or newer companies known as penny stocks. While the term may seem outdated, these stocks can still offer surprising value and opportunities for growth when they possess solid financial foundations.

As the United Kingdom's FTSE 100 and FTSE 250 indices experience downward pressure due to weak trade data from China, investors are increasingly cautious about the global economic landscape. In such an environment, identifying promising small-cap stocks like Concurrent Technologies can offer opportunities for those looking to navigate market volatility with a focus on companies that demonstrate resilience and potential for growth despite broader challenges.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Chesapeake Utilities stock snapshot after recent pullback Chesapeake Utilities (CPK) has slipped about 6% over the past month, even as its year to date gain sits near 6%, inviting a closer look at whether the recent weakness creates opportunity. See our latest analysis for Chesapeake Utilities. That 5.8% 1 month share price pullback looks more like a breather within a still positive trend. The 90 day share price return is in the low single digits, and a solid 5 year total shareholder return...

Helmerich & Payne recently announced that long-time CEO and director John Lindsay will retire after the March 4, 2026 Annual Meeting, with President Raymond John “Trey” Adams set to assume the CEO role and join the Board, while Lindsay remains as senior advisor through December 2026 to support the transition. This planned leadership handover, following a tenure marked by FlexRig innovation, technology acquisitions and international expansion, raises important questions about how Adams will...

Earlier this month, Herc Holdings Inc. announced it had priced US$600 million of 5.750% senior unsecured notes due 2031 and US$600 million of 6.000% notes due 2034, planning to use the proceeds along with its ABL credit facility to redeem US$1.20 billion of 5.50% senior notes due 2027, while its board also declared a US$0.70 quarterly dividend payable on December 26, 2025. This combination of refinancing longer-dated debt while maintaining a regular cash dividend highlights management’s...

In recent weeks, JOYY Inc. was highlighted for offering an around 9% total shareholder yield through dividends and buybacks, while trading below its net cash position and reporting strong growth in non-live streaming segments such as BIGO Ads and e-commerce SaaS. An interesting angle is JOYY’s push into AI-driven AdTech and planned 2026 iOS expansion, which could further shift its revenue mix toward higher-margin, advertising-led and software-based businesses. We’ll now explore how JOYY’s...

IDEAYA Biosciences (IDYA) just hit a key clinical milestone, completing enrollment in its pivotal OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with additional IND clearances quietly broadening the pipeline behind that lead asset. See our latest analysis for IDEAYA Biosciences. The clinical momentum around darovasertib and fresh IND wins has helped IDEAYA build a strong backdrop, with a roughly 36 percent 3 month share price return and a standout 5 year total shareholder...

Key Insights Significantly high institutional ownership implies Hogy MedicalLtd's stock price is sensitive to their...

In recent days, Dimerix announced that its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis completed recruitment and dosing of 286 adult patients, while Amicus Therapeutics drew fresh attention after new analyst coverage highlighted the company’s earnings potential. Together, the late-stage progress of DMX-200 and the wave of optimistic research coverage sharpen the focus on Amicus’s pipeline depth and prospects for earnings improvement. Now we’ll examine how this...

ORIX (TSE:8591) just confirmed a major leadership transition, with President Hidetake Takahashi set to become CEO from January 2026 as long serving chief Makoto Inoue moves into a Corporate Advisor role. See our latest analysis for ORIX. The leadership shuffle comes after a strong run, with a roughly 34 percent year to date share price return and a standout five year total shareholder return of about 245 percent. This suggests momentum is still firmly with ORIX as investors price in steady...

Investors can buy low cost index fund if they want to receive the average market return. But in any diversified...

Fitch’s decision to affirm Omega Healthcare Investors (OHI) at a BBB minus rating with a Stable Outlook puts fresh focus on how this healthcare REIT is balancing sector challenges with improving fundamentals. See our latest analysis for Omega Healthcare Investors. The Fitch call lands after a solid run, with Omega’s share price up 17.61% year to date and its one year total shareholder return of 22.34% adding to a three year total shareholder return of 101.55%. This suggests momentum in the...

Partners Group recently reported its Assets under Management as of 31 December 2025 and confirmed it will host a 2025 Business Update and 2026 Outlook presentation on 14 January 2026, offering fresh detail on its operations and plans. This combination of an AuM disclosure and upcoming outlook briefing gives investors a clearer window into how the firm is positioning its private-markets platform for the next phase of growth and product development. We’ll now explore how the latest AuM...

Johnson & Johnson (JNJ) just secured FDA approval for Akeega, a targeted combo therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer, a niche where treatment options have been thin yet clinically important. See our latest analysis for Johnson & Johnson. The FDA greenlight for Akeega lands while Johnson & Johnson’s share price has climbed strongly, with a roughly 48.7% year to date share price return and a robust 1 year total shareholder return of about 53.4%. This signals...

EastGroup Properties (EGP) is back on investors radar after a string of upbeat analyst calls tied to improving tenant demand, a clear rebound in leasing, and a fresh at the market equity program supporting 2026 growth plans. See our latest analysis for EastGroup Properties. Those moves and a freshly affirmed dividend backdrop have helped the stock grind higher, with a roughly 10 percent 3 month share price return and a near 12 percent one year total shareholder return signaling momentum is...

In December 2025, GameStop Corp. reported third-quarter 2025 results showing sales of US$821 million, down from US$860.3 million a year earlier, while net income rose to US$77.1 million from US$17.4 million and diluted earnings per share increased to US$0.13 from US$0.04. Despite relatively flat sales over the first nine months of 2025 at US$2.53 billion, the company generated US$290.5 million in net income, highlighting how cost reductions and a growing collectibles segment are supporting...

On 11 December 2025, Niron Magnetics announced a collaboration with Moog Inc. to develop and test advanced actuator solutions for guided munitions using domestically produced Iron Nitride magnet technology that reduces reliance on rare earth materials. This partnership aligns Moog with the U.S. Department of Defense’s Acquisition Transformation Strategy by supporting supply chain diversification and resilience in critical aerospace and defense applications. We’ll now examine how Moog’s work...

Key Insights LS ELECTRIC's significant public companies ownership suggests that the key decisions are influenced by...

Alnylam Pharmaceuticals recently reshaped its governance and capital structure, with two long-serving directors stepping down, a new independent director appointed, and a partial repurchase of US$34.4 million of its 1.00% convertible senior notes due 2027 at a total cost of US$51.9 million. The company’s upcoming inclusion in the Nasdaq 100 Index on December 22, alongside evolving board expertise and debt reduction, could broaden its investor base and refine its long-term growth profile in...